Advanced hepatocellular carcinoma
Conditions
Interventions
Study group (Arterial chemoembolization combined with lenvatinib and PD-1 inhibitor):None
Control group (Arterial chemoembolization combined with lenvatinib):None
Sponsors
Shandong Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Age >=18 years old; 2. BCLC stage B/C and meeting the diagnostic criteria of the "Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma"; 3. The Eastern Cooperative Oncology Group (ECOG) status score ranges from 0 to 1 4.Patients who have undergone radical treatment and experience recurrence can be included; 5.Child Pugh classification of liver function as A or B; 6.At least one measurable target lesion that meets the mRECIST criteria is present in the imaging examination.
Exclusion criteria
Exclusion criteria: 1.Diffuse distribution of HCC; 2. Patients who have received TACE, hepatic artery infusion chemotherapy, radiotherapy, targeted drugs or immunosuppressants in the past; 3.Accompanied by serious medical complications such as heart, lung, kidney, or coagulation dysfunction that cannot be improved through treatment; 4.There are severe manifestations of liver function impairment, such as refractory ascites, hepatic encephalopathy, or jaundice; 5. Patients with complete blockage of the main portal vein by cancer thrombus and no rich collateral circulation formed; 6.Follow up time is less than 3 months or there is no complete clinical data; 7.History of malignant tumors other than liver cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactZhu Qiang
Shandong Provincial Hospital
Outcome results
None listed